U.S. to Provide $4 Billion for International COVID-19 Vaccine Program
FRIDAY, Feb. 19, 2021 -- The United States will soon start providing $4 billion for COVAX, an international program to buy and distribute COVID-19 vaccines to poor countries.
White House officials said President Joe Biden will make the announcement Friday at a G-7 meeting and will also encourage other members of the group to make good on their pledges to the World Health Organization initiative, the Associated Press reported.
The $4 billion in funding was approved by Congress in December and will be doled out through 2022. The United States is committed to working through COVAX to ensure "equitable distribution of vaccines and funding globally," White House Press Secretary Jen Psaki told reporters on Thursday.
The COVAX program has already missed its own goal of beginning COVID-19 vaccinations in poor countries at the same time that shots were rolled out in rich countries, the AP reported. The WHO says COVAX needs $5 billion in 2021.
U.N. Secretary-General Antonio Guterres said Wednesday that 130 countries have not received a single dose of the vaccine and declared that "at this critical moment, vaccine equity is the biggest moral test before the global community."
© 2021 HealthDay. All rights reserved.
Posted: February 2021
Further Support and Information on COVID-19
Read this next
THURSDAY, March 4, 2021 -- The COVID-19 pandemic has had a disruptive effect on pediatric oncology services, according to a study published online March 3 in The Lancet Child...
WEDNESDAY, March 3, 2021 -- Self-reported symptoms of behavioral health issues remain high as the COVID-19 pandemic continues, according to a research letter published online Feb....
WEDNESDAY, March 3, 2021 -- More than 200,000 Americans signed up for health insurance in the first two weeks after HealthCare.gov was reopened for a three-month special...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.